These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24120379)

  • 1. Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag).
    Novitzky N; Davison G; Abdulla R; Mowla S
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1753-9. PubMed ID: 24120379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1.
    Dreger P; Viehmann K; Steinmann J; Eckstein V; Müller-Ruchholtz W; Löffler H; Schmitz N
    Exp Hematol; 1995 Feb; 23(2):147-54. PubMed ID: 7530212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
    Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
    Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
    Chakrabarti S; Hale G; Waldmann H
    Transplant Proc; 2004 Jun; 36(5):1225-7. PubMed ID: 15251298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells.
    Lim CK; Sun L; Feng Q; Law P; Chua WT; Lim SN; Hwang WY
    J Hematol Oncol; 2008 Oct; 1():19. PubMed ID: 18947412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early recovery of natural killer cells post T-cell depleted allogeneic stem cell transplantation using alemtuzumab "in the bag".
    Davison GM; Opie JJ; Davids SFG; Mohammed R; Novitzky N
    Transpl Immunol; 2024 Jun; 84():102045. PubMed ID: 38641148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.
    Novitzky N; Thomas V; du Toit C
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):584-8. PubMed ID: 23270985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation.
    Roex MCJ; Wijnands C; Veld SAJ; van Egmond E; Bogers L; Zwaginga JJ; Netelenbos T; von dem Borne PA; Veelken H; Halkes CJM; Falkenburg JHF; Jedema I
    Cytotherapy; 2021 Jan; 23(1):46-56. PubMed ID: 32948458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
    Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
    Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
    Kanda Y; Oshima K; Kako S; Fukuda T; Uchida N; Miyamura K; Kondo Y; Nakao S; Nagafuji K; Miyamoto T; Kurokawa M; Okoshi Y; Chiba S; Ohashi Y; Takaue Y; Taniguchi S
    Am J Hematol; 2013 Apr; 88(4):294-300. PubMed ID: 23450467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N; Thomas V; du Toit C
    Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell processing protocol for allogeneic peripheral blood stem cells mobilized by granulocyte colony-stimulating factor.
    Suzue T; Kawano Y; Takaue Y; Kuroda Y
    Exp Hematol; 1994 Aug; 22(9):888-92. PubMed ID: 7520392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
    Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.
    Giralt S
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S36-43. PubMed ID: 16720202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Mutation Frequency of the
    Loeff FC; Falkenburg JHF; Hageman L; Huisman W; Veld SAJ; van Egmond HME; van de Meent M; von dem Borne PA; Veelken H; Halkes CJM; Jedema I
    J Immunol; 2018 Mar; 200(6):2199-2208. PubMed ID: 29427418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries.
    Clarke E; Potter MN; Hale G; Waldmann H; Lankester A; Cornish JM; Steward CG; Marks DI; Oakhill A; Pamphilon DH
    Bone Marrow Transplant; 1998 Jul; 22(2):117-24. PubMed ID: 9707017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.